Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2023 16:01 ET
|
Annexon Biosciences
BRISBANE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)
October 10, 2023 06:30 ET
|
Annexon Biosciences
ANX005 Granted Orphan Drug Designation by the European Medicines Agency for the Treatment of GBS Target Enrollment Achieved in Phase 3 Pivotal Study of ANX005 in GBS Representing the Company’s Third...
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
September 19, 2023 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2023 16:01 ET
|
Annexon Biosciences
BRISBANE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
August 07, 2023 06:30 ET
|
Annexon Biosciences
ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward ...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2023 16:01 ET
|
Annexon Biosciences
BRISBANE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy
July 30, 2023 12:00 ET
|
Annexon Biosciences
Additional analyses support consistent protection from vision loss Annexon to engage with regulatory agencies to determine optimal path forward for ANX007 Company to hold investor conference call on...
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
July 27, 2023 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for...
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
July 24, 2023 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for...
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
May 24, 2023 16:01 ET
|
Annexon Biosciences
ARCHER data support ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection against vision loss in both foveal and non-foveal patients through...